Blogs

Oncology News Burst from the FDA: FDA Approves Nogapendekin Alfa Inbakicept-pmln for BCG-unresponsive Non-muscle Invasive Bladder Cancer

By SITC Communications posted yesterday
Be the first person to recommend this.
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position on the safety or efficacy of the product or therapy described. ...
0 comments

Announcing Increasing Access to IO: A Global Webinar Series

By SITC Advocacy posted yesterday
Be the first person to recommend this.
The Global Access and Impact Committee, in collaboration with the Diversity, Equity, and Inclusion Committee, is pleased to launch SITC's first educational program crafted specifically for international audiences, titled " Increasing Access to IO: A Global Webinar Series ". This series will serve as an excellent resource for all stakeholders interested in learning about the application of immunotherapy, as well as the infrastructure and resources needed to support the expansion of access around the globe. This series will focus on the nuances of applying the latest scientific and clinical advances in cancer immunotherapy around the globe. These free-to-attend ...
0 comments

SITC Publishes Recommendations on Optimal Intratumoral Immunotherapy Clinical Trial (IICT) Design

By SITC Communications posted 2 days ago
Be the first person to recommend this.
MILWAUKEE – The Society for Immunotherapy of Cancer (SITC) is pleased to announce the publication of a new manuscript “ Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from pre-malignant to metastatic disease ” in the Journal for ImmunoTherapy of Cancer . While intratumoral immunotherapies have the potential to boost anti-tumor immune responses to overcome immunosuppressive tumor microenvironments, phase III trials evaluating them in late-stage disease have had limited success to date, in part due to the complex nature of these trials not fully adapted to assess local therapies. The aim for ...
0 comments

SITC Publishes Recommendations  on Intratumoral Immunotherapy Clinical Trial Design

By SITC Scientific Publications News posted 6 days ago
Be the first person to recommend this.
On behalf of the society and the SITC Intratumoral Immunotherapy Clinical Trials Manuscript Development Group, we are pleased to announce the publication of a new manuscript “ Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from pre-malignant to metastatic disease ” in the Journal for ImmunoTherapy of Cancer . While intratumoral immunotherapies have the potential to boost anti-tumor immune responses to overcome immunosuppressive tumor microenvironments, phase III trials evaluating them in late-stage disease have had limited success to-date, in part due to the complex nature of these trials not ...
0 comments

JITC Digest April 2024

By JITC Publications posted 8 days ago
Be the first person to recommend this.
INSIDE THIS ISSUE: Letter from the Editor | JITC Editor Picks | Interview with JITC 's Incoming Editor-in-Chief | Popular Archive Articles Letter from the Editor Hello JITC Readers, Welcome to the latest edition of the JITC Digest. This month I am excited to share an interview with JITC ’s Incoming Editor-in-Chief Michael T. Lotze, MD. As Dr. Lotze continues to transition into his role, I encourage you to check out the special feature to learn more about his time with JITC thus far as well as his extensive career. There are also some fascinating stories and personal insights ...
0 comments

Meet JITC’s Incoming Editor-in-Chief – Michael T. Lotze, MD

By JITC Publications posted 10 days ago
1 person recommends this.
Dr. Michael T. Lotze is Incoming Editor-in-Chief for the Journal for ImmunoTherapy of Cancer ( JITC ). As he transitions into his role with JITC , learn more about Dr. Lotze’s career, interest in JITC , and personal life. Career What inspired you to become a researcher? Dr. Lotze: My earliest experiences in research were a disaster; I worked on a project at Northwestern University over the summer after my sophomore year on the rat testicular hexokinase and was so flummoxed (and out of money) that I went back to working as a scrub technician in the operating room. A year later, as a way to do my first international ...
0 comments

April 2024 JITC Reading List: Dr. Marcela Maus

By JITC Publications posted 13 days ago
Be the first person to recommend this.
The following articles have been recommended for further reading in the field of cancer immunotherapy by JITC 's Immune Cell Therapies and Immune Cell Engineering Section Editor Dr. Marcela Maus . “A versatile CRISPR-Cas13d platform for multiplexed transcriptomic regulation and metabolic engineering in primary human T cells” by Victor Tieu et al Cell (2024) Summary : CRISPR technologies have begun to revolutionize T cell therapies; however, conventional CRISPR-Cas9 genome-editing tools are limited in their safety, efficacy, and scope. To address these challenges, we developed multiplexed effector guide arrays (MEGA), a platform for ...
0 comments

SITC and the NCI Announce Fourth Year of Collaboration with the New AI in IO: Computational Immuno-oncology Webinar Series

By Thomas Martin posted 13 days ago
1 person recommends this.
MILWAUKEE – The Society for Immunotherapy of Cancer (SITC), the world’s leading member-driven organization dedicated to improving patient outcomes by advancing the science and application of cancer immunotherapy, is pleased to announce their collaboration with the National Cancer Institute (NCI), part of the National Institutes of Health, on the fourth Computational Immuno-oncology Webinar Series. This year’s series will focus specifically on the application of artificial intelligence (AI) in the field of immuno-oncology (IO). As such, the series has been rebranded to “AI in IO: SITC-NCI Computational Immuno-oncology Webinar Series”. “The potential for ...
0 comments

AACR Annual Meeting 2024

By Thomas Martin posted 14 days ago
2 people recommend this.
The Society for Immunotherapy of Cancer (SITC) is pleased to present highlights of the latest advances in immunotherapy emerging from the 2024 AACR Annual Meeting. Below is a recap of highlighted research presented from Friday, April 5–Wednesday, April 10, 2024. 2024 Scientific Highlights Long-term follow-up of CD70-targeting allogeneic CAR T cell therapy for refractory clear cell renal cell carcinoma CT002. CTX130 allogeneic CRISPR-Cas9-engineered chimeric antigen receptor (CAR) T cells in patients with advanced clear cell renal cell carcinoma: Long-term follow-up and translational data from the phase 1 COBALT-RCC study Samer A. Srour ...
0 comments

SITC and Association of Cancer Care Center collaborate on new webinar

By SITC Advocacy posted 22 days ago
Be the first person to recommend this.
SITC and ACCC have collaborated on a new webinar aimed at providing further details on the Expanding Access to Cellular and Bispecific Therapy Workshop. This webinar featured expert speakers that provided perspective and thoughts on how to further access to these therapies in the community setting. A full recording of the webinar can be found at this LINK.
0 comments

Immune Monitor - March 2024

By SITC Communications posted 29 days ago
Be the first person to recommend this.
A Message from the President Last month, we witnessed the monumental FDA approval of lifileucel, a first-in-class tumor infiltrating lymphocyte (TIL) therapy, for patients with unresectable or metastatic melanoma. Notably, the approval of lifileucel also marks the first approval of any cellular therapy for the treatment of solid tumors, thus significantly expanding its application beyond hematologic malignancies. This critical milestone event underscores the importance of supporting the biotech ecosystem to ensure promising novel immunotherapeutics have a pathway to approval for patients in need. The Society for Immunotherapy of Cancer (SITC) plays ...
0 comments

SITC provides comment on Draft FDA Guidance

By SITC Advocacy posted 29 days ago
Be the first person to recommend this.
SITC has provided full comments on a recently released FDA Draft Guidance: "Potency Assurance for Cellular and Gene Therapy Products". Please find the letter in its entirety HERE .
0 comments

JITC Digest March 2024

By JITC Publications posted 03-20-2024
Be the first person to recommend this.
Inside this Issue: Letter from the Editor | JITC Editor Picks | JITC Meet-the-Editor Session | Popular Archive Articles Letter from the Editor Hello JITC Readers, Welcome to the March edition of the JITC Digest. As we approach the end of the month, it means the 2024 American Association for Cancer Research (AACR) Annual Meeting is just around the corner. I look forward to seeing those of you who will be joining me in beautiful San Diego. I also encourage you to visit the SITC booth in the exhibition hall during the conference. Our Deputy Editor-in-Chief, Sjoerd ...
0 comments

SITC provides meeting coverage on March 15th ODAC meeting

By SITC Advocacy posted 03-20-2024
Be the first person to recommend this.
SITC has provided meeting coverage of the March 15th ODAC meeting. The coverage includes an overview of the discussion, including representation of the different stakeholder perspectives on each issue, as well as a summary of all recommendations from ODAC. The coverage can be found in its entirety HERE .
0 comments

March 15, 2024: Meeting of the Oncologic Drugs Advisory Committee

By Thomas Martin posted 03-19-2024
2 people recommend this.
The Society for Immunotherapy of Cancer (SITC) is pleased to present a summary of the U.S. Food & Drug Administration (FDA) Meeting of the Oncologic Drugs Advisory Committee (ODAC) . Below is a recap of highlighted research presented from Friday, March 15, 2024. Morning session: Supplemental biologics license application (sBLA) 125746.7 for ciltacabtagene autoleucel Ciltacabtagene autoleucel (cilta-cel, CARVYKTI), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell therapy initially obtained approval for adult patients with relapsed or refractory multiple myeloma (r/r MM) after four or more prior lines ...
0 comments

March 2024 JITC Reading List: Dr. Jason Luke

By JITC Publications posted 03-18-2024
Be the first person to recommend this.
The following articles have been recommended for further reading in the field of cancer immunotherapy by JITC's Clinical/Translational Cancer Immunotherapy co-Section Editor Dr. Jason Luke . “Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer” by Memon et al Cancer Cell (2024) Summary: Although immunotherapy with PD-(L)1 blockade is routine for lung cancer, little is known about acquired resistance. Among 1,201 patients with non-small cell lung cancer (NSCLC) treated with PD-(L)1 blockade, acquired resistance is common, occurring in >60% of initial responders. Acquired resistance shows ...
0 comments

Announcing SITC's 2024 Advances in Cancer Immunotherapy Series

By SITC Scientific Publications News posted 03-15-2024
Be the first person to recommend this.
SITC 2024 Advances in Cancer Immunotherapy Series We’re excited to announce SITC’s 2024 Advances in Cancer Immunotherapy (ACI) educational series, which offers in-depth clinical training in immunotherapy treatment for a variety of disease states and topics from experts in the field. The ACI programs aim to engage practicing clinical oncologists, advanced practitioners, nurses, pharmacists, emergency physicians, and other allied health professionals who wish to learn the most up-to-date clinical data for these treatments in order to inform and integrate them into their own clinical practice. SITC ACI attendees benefit from: Updates on the ...
0 comments

SITC provides letter to Oncologic Drug Advisory Committee (ODAC)

By SITC Advocacy posted 03-12-2024
Be the first person to recommend this.
SITC has provided a letter to ODAC providing insight into the implications of control arm crossover use within clinical trials. The letter also provides support for the use of Progression Free Survival as a viable surrogate endpoint within clinical trials. Please find the letter in its entirety HERE .
0 comments

Oncology News Burst from the FDA: FDA Approves Nivolumab in Combination with Cisplatin and Gemcitabine for Unresectable or Metastatic Urothelial Carcinoma

By SITC Communications posted 03-08-2024
Be the first person to recommend this.
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position on the safety or efficacy of the product or therapy described. ...
0 comments

SITC on the Hill 2024 - Thank you Dr. Tarhini

By SITC Advocacy posted 03-05-2024
Be the first person to recommend this.
Thank you to Dr. Ahmad Tarhini from Moffitt Cancer Center and Research Institute for partici pating in SITC’s 2024 Capitol Hill Visits. Dr. Tarhini met with Senator Rubio’s and Representative Castor’s offices to advocate for inclusion of SITC’s FY25 appropriations language aimed at improving Immunotherapy resear ch i n early sta ge diseases. See SITC’s full FY25 language here: SITC FY25 Appropriations Language.pdf
0 comments